Layla Zulfa
In a landmark development for neurotechnology, Science Corporation, the brainchild of former Neuralink co-founder and president Max Hodak, has announced a significant milestone: the successful implantation of its vision-restoring device, PRIMA, into a patient suffering from Stargardt disease. This breakthrough represents more than just a medical triumph; it marks a pivotal shift in the trajectory of brain-computer interface (BCI) technology, moving from experimental laboratory curiosity to a practical tool for restoring lost human function.
While the tech industry has been fixated on the promise of mind-controlled computing, Science Corporation is taking a more grounded, patient-centric approach. By focusing on the central nervous system—starting with the retina—Hodak and his team are building a foundation that could eventually bridge the gap between biological limitations and artificial augmentation.
The Core Achievement: Restoring Vision Through Silicon
Stargardt disease, an inherited condition that leads to the progressive death of light-sensing cells in the retina, has long been considered incurable. It manifests as a central blind spot that gradually expands, robbing individuals of their ability to read, drive, or recognize faces. Approximately 150,000 people worldwide live with this debilitating condition.
The PRIMA system operates on a elegant premise: the brain is, in essence, a sophisticated computer, and vision is simply the processing of electrical signals transmitted via the optic nerve. By bypassing damaged photoreceptors, Science Corporation uses a 2mm-by-2mm chip to "speak" the language of the optic nerve directly.
During a clinical trial at the Sydney Eye Hospital in Australia, the first patient to receive the implant demonstrated immediate, tangible progress. Following a brief rehabilitation period, the patient reported the ability to identify letters and, remarkably, read entire words—a testament to the system’s efficacy in restoring functional visual perception.
Chronology of a Medical Breakthrough
The path to this moment has been characterized by methodical development rather than the rapid-fire hype often associated with Silicon Valley startups.
- 2021: Max Hodak departs Neuralink to found Science Corporation, pivoting away from the direct-brain insertion model toward a broader vision of neural engineering.
- 2025 (December): The company publicly clarifies its BCI architecture, revealing a sensor designed to rest on the surface of the brain, avoiding the risks associated with invasive tissue penetration.
- 2026 (April): Science Corporation signals its intent to begin human trials, setting the stage for its first sensor placement.
- 2026 (May): The first Stargardt disease patient undergoes the hour-long procedure to receive the PRIMA implant.
- 2026 (July): The PRIMA device achieves regulatory approval in Europe for treating geographic atrophy, a severe form of age-related macular degeneration.
- 2026 (October): At TechCrunch Disrupt, Hodak formally announces the clinical success of the Stargardt trial, outlining the path toward "native acuity" vision.
Understanding the Mechanics of the PRIMA Implant
The PRIMA device is not a full-retina replacement, but rather a high-precision, sub-retinal prosthesis. The procedure is surprisingly non-disruptive, requiring only an hour of surgical time to place the chip in the back of the eye where photoreceptors have ceased to function.
Once implanted, the patient wears specialized glasses equipped with cameras. These cameras capture the visual environment and transmit that data wirelessly to the chip. The chip then acts as a transducer, converting visual information into electrical impulses that the optic nerve can deliver to the brain.
"It is like looking through a straw," Hodak explained during his keynote. "It is not full-field color vision. It is a patch of central vision that is black and white, but it is sharp. It is high-contrast sharp, and the patient can see a couple of letters at a time."
The company is not content with this current limitation. Their roadmap for the next five years is aggressive: they aim to scale the size of the implant, compensate for the natural curvature of the eye, and decrease the size of the electrodes to achieve visual resolution that mimics the sharpness of natural, healthy human sight.
Beyond Vision: The Broader BCI Vision
While PRIMA is the current flagship, it is merely the "proof of concept" for Science Corporation’s broader ambition. Hodak argues that the distinction between a "retinal prosthesis" and a "brain-computer interface" is largely semantic.
"The retina is part of the central nervous system," Hodak noted. "We consider cochlear implants, retinal prostheses, and motor prostheses all to be different types of BCIs. If you can get the optic nerve to signal the rest of the brain correctly, you can provide vision. If you can do the same for the motor cortex, you can provide mobility."
The Next Frontier: Neurodegeneration and Stroke
Science Corporation’s long-term strategy involves moving from sensory restoration to the treatment of complex neurological conditions. The company is currently exploring clinical indications for "a neurodegenerative disease that everybody has heard of," though they remain tight-lipped about the specific trial details.
Furthermore, they are evaluating how BCIs can be used for stroke recovery. In cases where parts of the brain have suffered irreversible tissue death, the company envisions a future where "bridging" technology connects two healthy areas of the brain to restore lost functionality. By creating new cortical pathways, Science Corporation hopes to enable the brain to "re-map" its own capabilities—a feat that conventional electrodes cannot achieve.
Implications for Health Span and Human Longevity
Perhaps the most ambitious aspect of Hodak’s mission is the shift from treating isolated diseases to extending the "health span" of the aging population.
"We aren’t designing for healthy 40-year-olds," Hodak clarified. Instead, the company anticipates that by the time individuals reach 60 or 70, the integration of some form of neural interface may become as routine as cataract surgery or hearing aids.
This philosophy aligns with a growing movement in biotechnology that views the human body as a biological machine subject to wear and tear. If a component fails—whether it is a photoreceptor in the eye or a neural pathway in the motor cortex—a BCI could theoretically provide the necessary "patch" to keep the system operational.
Addressing the Critics: A Different Approach to Safety
The tech world has been captivated by the "Elon Musk-style" of BCI, which often involves thin, flexible threads inserted directly into brain tissue. Science Corporation, however, has consciously taken a different route.
Their sensor design rests on the surface of the brain, rather than inside it. This is a crucial distinction in the medical community. By avoiding the trauma of penetrating the blood-brain barrier and piercing sensitive neural tissue, the company hopes to reduce the risks of inflammation, scar tissue buildup, and long-term rejection—factors that have historically hindered the commercial viability of invasive brain implants.
Looking Ahead: The Future of "Engineered Brains"
While the immediate focus is on restoring vision and helping stroke patients, the long-term vision of Science Corporation is profound. Hodak explicitly stated that the company’s ultimate goal is to understand how the brain creates the mind and to learn to build "engineered brains."
This is a statement that touches on the philosophical as much as the biological. If we can map the electrical potential of thoughts, memories, and sensory inputs, the potential for human augmentation becomes theoretically limitless.
For now, the thousands of people suffering from Stargardt disease and other degenerative conditions provide the necessary focus. By grounding their revolutionary technology in the immediate, desperate needs of patients, Science Corporation is proving that the most futuristic innovations are those that solve the most ancient problems of human suffering.
As the next generation of the PRIMA chip prepares for human trials in the coming year, the world will be watching. If Science Corporation can deliver on its promise to reach native-level visual acuity within five years, it will not only have changed the field of ophthalmology—it will have rewritten the rules of what it means to live, see, and interact with the world through the power of the connected mind.
Iffa Jayyana
Suro Senen
